What were Adasuve’s sales like (and what happened after launch)?
Adasuve (loxapine inhalation powder) has been marketed for acute agitation associated with schizophrenia or bipolar disorder, and its sales performance has largely reflected how often clinicians choose an inhaled rescue option versus alternatives. Publicly available sales data for specific years and units is not provided in the source material available here, so I can’t quote definitive revenue figures without a sales dataset or a specific report to pull from.
If you share the year range you care about (for example, 2017–2019 or 2020–2023) or whether you mean global vs. U.S. sales, I can narrow the answer to that period.
Who made Adasuve and why sales can swing?
Adasuve is associated with marketing and commercialization decisions by its manufacturer. Sales can change quickly when payers tighten coverage, formularies shift, competitors gain preference, or uptake depends on setting (for example, emergency department vs. inpatient psychiatry). Without manufacturer/sales-report data in the provided material, I can’t attribute Adasuve’s sales movements to specific payer or competitor events here.
Are patent or exclusivity issues affecting Adasuve’s market share?
If your goal is to understand sales trends via “generic/biosimilar pressure” or exclusivity timing, patent and exclusivity timelines matter. One place to check for relevant patent coverage and potential generic entry risk is DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Adasuve” on that site).
What sales metric do you mean?
“Adasuve sales” can mean different things. Common interpretations include:
- Annual prescription units (or script counts)
- Net sales or revenue (often reported by fiscal year)
- U.S. vs. global totals
- Wholesaler vs. retail metrics
Tell me which metric and time window you want, and I’ll format the answer accordingly.
Sources
- [1] https://www.drugpatentwatch.com/